OPRD1 Protéine

N° du produit ABIN7538455

Détail du produit

Antigène: OPRD1 (Opioid Receptor, delta 1 (OPRD1))

Type de proteíne: Synthetic Nanodisc

Origine: Humain

Source: Mammalian Cells

Fonction: Human OPRD full length protein-synthetic nanodisc

Attributs du produit: Unlike other membrane scaffold protein (MSP) Nanodisc on the market, our synthetic Nanodisc can be prepared directly from the cells. The polymers used during this process have a dual function. It dissolves the cell membranes, like the detergent, and uses cellular phospholipids to form Nanodisc around the membrane proteins. The target protein embedded Nanodiscs can then be purified.

Information d'application

Commentaires:

Advantages of Synthetic Nanodiscs:

• Highly purified membrane proteins
• High solubility in aqueous solutions
• High stability
• Proteins are in a native membrane environment and remain biologically active
• No detergent and can be used for cell-based assays
• No MSP backbone proteins

Limitations of Synthetic Nanodiscs:

• Intolerant to acids and high concentrations of divalent metal ions

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

Date de péremption: 12 months

Détail du antigène

Antigène: OPRD1 (Opioid Receptor, delta 1 (OPRD1))

Autre désignation: OPRD (OPRD1 Produits)

Synonymes: OPRD Protein, DOR-1 Protein, Nbor Protein, mDOR Protein, opioid receptor delta 1 Protein, opioid receptor, delta 1 Protein, OPRD1 Protein, Oprd1 Protein

Sujet: G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.[UniProtKB/Swiss-Prot Function]

Poids moléculaire: The human full length OPRD protein has a MW of 40.4kDa

UniProt: P41143

Pathways: Protein targeting to Nucleus